Ontology type: schema:ScholarlyArticle Open Access: True
2019-12
AUTHORSUlrich Costabel, Carlo Albera, Marilyn K. Glassberg, Lisa H. Lancaster, Wim A. Wuyts, Ute Petzinger, Frank Gilberg, Klaus-Uwe Kirchgaessler, Paul W. Noble
ABSTRACTData from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC ≥50% and DLco ≥35%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180 weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF. More... »
PAGES55
http://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2
DOIhttp://dx.doi.org/10.1186/s12931-019-1021-2
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1112739118
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/30866942
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"Ruhrlandklinik, University Hospital, University of Duisburg-Essen, T\u00fcschener Weg, 45239, Essen, Germany"
],
"type": "Organization"
},
"familyName": "Costabel",
"givenName": "Ulrich",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Turin",
"id": "https://www.grid.ac/institutes/grid.7605.4",
"name": [
"Department of Clinical and Biological Sciences, Interstitial and Rare Lung Disease Unit, University of Turin, Regione Gonzole 10, 10043, Orbassano, Italy"
],
"type": "Organization"
},
"familyName": "Albera",
"givenName": "Carlo",
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Miami Health System",
"id": "https://www.grid.ac/institutes/grid.418456.a",
"name": [
"Departments of Medicine, Surgery, and Pediatrics, University of Miami Health System, 1321 14th Street, Suite 510, 33125, Miami, FL, USA"
],
"type": "Organization"
},
"familyName": "Glassberg",
"givenName": "Marilyn K.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Vanderbilt University Medical Center",
"id": "https://www.grid.ac/institutes/grid.412807.8",
"name": [
"Department of Medicine, Vanderbilt University Medical Center, 1211 Medical Center Drive, 37232, Nashville, TN, USA"
],
"type": "Organization"
},
"familyName": "Lancaster",
"givenName": "Lisa H.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universitaire Ziekenhuizen Leuven",
"id": "https://www.grid.ac/institutes/grid.410569.f",
"name": [
"Department of Respiratory Medicine, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium"
],
"type": "Organization"
},
"familyName": "Wuyts",
"givenName": "Wim A.",
"type": "Person"
},
{
"affiliation": {
"name": [
"Accovion GmbH, Helfmann-Park 10, 65760, Eschborn, Germany"
],
"type": "Organization"
},
"familyName": "Petzinger",
"givenName": "Ute",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Roche (Switzerland)",
"id": "https://www.grid.ac/institutes/grid.417570.0",
"name": [
"F. Hoffmann-La Roche, Ltd., Konzem-Hauptsitz, Grenzacherstrasse 124, CH-4070, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Gilberg",
"givenName": "Frank",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Roche (Switzerland)",
"id": "https://www.grid.ac/institutes/grid.417570.0",
"name": [
"F. Hoffmann-La Roche, Ltd., Konzem-Hauptsitz, Grenzacherstrasse 124, CH-4070, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Kirchgaessler",
"givenName": "Klaus-Uwe",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Cedars-Sinai Medical Center",
"id": "https://www.grid.ac/institutes/grid.50956.3f",
"name": [
"Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, 90048, Los Angeles, CA, USA"
],
"type": "Organization"
},
"familyName": "Noble",
"givenName": "Paul W.",
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/s0140-6736(11)60405-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009123817"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1164/rccm.2009-040gl",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009587829"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1402582",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1013090473"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1164/rccm.201006-0894ci",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016956304"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1378/chest.10-2572",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033922879"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa1402584",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1048572484"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00408-016-9912-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050449289",
"https://doi.org/10.1007/s00408-016-9912-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00408-016-9912-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050449289",
"https://doi.org/10.1007/s00408-016-9912-1"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1111/resp.12989",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083687170"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1159/000479976",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1091608456"
],
"type": "CreativeWork"
}
],
"datePublished": "2019-12",
"datePublishedReg": "2019-12-01",
"description": "Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited, since this sub-population is usually excluded from clinical trials. These exploratory post-hoc analyses of the open-label, long-term extension study RECAP (NCT00662038) aimed to assess the efficacy and safety of pirfenidone in patients with more advanced IPF. Patients were categorised according to the extent of lung function impairment at baseline: more advanced (percent predicted FVC <50% and/or DLco <35%) and less advanced (percent predicted FVC \u226550% and DLco \u226535%).Overall, 596 patients with baseline FVC and/or DLco values available were included in the analyses; 187 patients had more advanced disease, and 409 patients had less advanced disease. Mean percent predicted FVC declined throughout 180\u2009weeks of treatment in both more and less advanced disease subgroups. Both subgroups exhibited a similar pattern of adverse events; however, adverse events related to IPF progression were experienced by a higher proportion of patients with more advanced versus less advanced disease. Discontinuation rates due to any reason, adverse events related to IPF progression, or deaths were each higher in the more advanced versus the less advanced disease subgroup.These analyses found that longer-term pirfenidone treatment resulted in a similar rate of lung function decline and safety profile in patients with more advanced versus less advanced IPF, and the data suggest that pirfenidone is efficacious, well tolerated, and a feasible treatment option in patients with more advanced IPF.",
"genre": "non_research_article",
"id": "sg:pub.10.1186/s12931-019-1021-2",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1028525",
"issn": [
"1465-9921",
"1465-993X"
],
"name": "Respiratory Research",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "20"
}
],
"name": "Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis",
"pagination": "55",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"63a48542f9341afff0747f784442db4727d98670737b2b296141ae1b4f48be0c"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"30866942"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101090633"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12931-019-1021-2"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1112739118"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12931-019-1021-2",
"https://app.dimensions.ai/details/publication/pub.1112739118"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T13:19",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78950_00000001.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1186%2Fs12931-019-1021-2"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12931-019-1021-2'
This table displays all metadata directly associated to this object as RDF triples.
163 TRIPLES
21 PREDICATES
38 URIs
21 LITERALS
9 BLANK NODES